Skip to main
SKIN

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 0%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

SkinHealth Systems is executing better in an increasingly competitive market, with revenue declining -8% y/y in 2Q26 but adjusted EBITDA exceeding guidance due to gross margin expansion and disciplined expense management. The company's strategic priorities, including the launch of a new rental program and expansion into adjacent categories, provide additional potential for growth. Key innovation catalysts include a new rental program, upcoming product launches, and continued traction in existing products. While there are risks of execution and competition, the company's strong cash position and ongoing development of its next-generation platform provide a solid foundation for future growth.

Bears say

SkinHealth Systems is facing ongoing challenges in its medical aesthetics business due to declines in equipment sales and softness in the EMEA region. This has resulted in reduced revenue and profitability, and the company's guidance for the remainder of the year is below expectations. There are also concerns over the company's ability to generate positive free cash flow and manage its longer-term debt obligations. In addition, SkinHealth Systems faces competitive pressures and regulatory risks that could further impact its revenue and brand reputation.

SKIN has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Hold based on their latest research and market trends.

According to 4 analysts, SKIN has a Hold consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.